New obesity drug petrelintide put to the test in early study
NCT ID NCT07338214
First seen Jan 16, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This completed Phase 1 study tested a single injection of petrelintide, a drug being developed for weight management, in 48 adults with a BMI of 27 or higher. The goal was to see if different concentrations of the same dose change how the body absorbs and processes the drug, and to check for safety differences. Participants were monitored for about 50 days with blood tests and clinic visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.